IVAX SUB TEVA PHARMS received FDA approval for ANDA076089 on June 9, 2004, paving the way for the launch of a new generic drug that barring patent challenges is expected to capitalize on an imminent U.S. market vacuum.
IVAX SUB TEVA PHARMS received FDA approval for ANDA076089 on June 9, 2004, paving the way for the launch of a new generic drug that barring patent challenges is expected to capitalize on an imminent U.S. market vacuum.